This inventor holds 1 USPTO granted patent. Top assignee: Japanese Foundation for Cancer Research. Active years: 2019.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2019
Title: Norihisa Shindo: Innovator in Cancer Research
Introduction
Norihisa Shindo is a prominent inventor based in Tokyo, Japan. He has made significant contributions to the field of cancer research through his innovative inventions. His work focuses on developing tools that enhance our understanding of cell division and cancer treatment.
Latest Patents
One of Shindo's notable patents is the "Fluorescent separase activity sensor." This invention addresses the need for a separase sensor that can visualize separase activity in living cells. The sensor is designed to analyze cell division and facilitate the screening of anticancer agents. It incorporates two types of fluorescent proteins that differ in fluorescence wavelength, strategically placed at both ends of an amino acid sequence containing a separase cleavage site. This innovative approach allows researchers to specify the timing and location of separase activation within a cell.
Career Highlights
Norihisa Shindo is affiliated with the Japanese Foundation for Cancer Research, where he continues to advance his research. His work has garnered attention for its potential applications in cancer treatment and cell biology. With a focus on practical solutions, Shindo aims to contribute to the development of effective anticancer therapies.
Collaborations
Shindo collaborates with esteemed colleagues such as Toru Hirota and Kazuki Kumada. Their combined expertise enhances the research efforts at the Japanese Foundation for Cancer Research, fostering innovation in the field.
Conclusion
Norihisa Shindo's contributions to cancer research through his patented inventions exemplify the impact of innovative thinking in science. His work not only advances our understanding of cell division but also holds promise for future cancer therapies.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile